Validation of the PRIMA-prognostic index for patients treated with rituximab plus chemotherapy and refinement of prognostic parameters for patients on rituximab plus lenalidomide in the phase III relevance trial Meeting Abstract
| Authors: | Julia, E.; Fowler, N. H.; Bachy, E.; Feugier, P.; Bouabdallah, R.; Tilly, H.; Palomba, M. L.; Fruchart, C.; Libby, E. N. 3rd; Casasnovas, R. O.; Flinn, I. W.; Haioun, C.; Maisonneuve, H.; Ysebaert, L.; Bartlett, N. L.; Bouabdallah, K.; Brice, P.; Ribrag, V.; Daguindau, N.; Le Gouill, S.; Pica, G. M.; Martín, A.; Lopez-Guillermo, A.; Larouche, J. F.; Ando, K.; da Silva Maria, G.; André, M.; Wu, K. L.; Sehn, L. H.; Tobinai, K.; Cartron, G.; Delarue, R.; Czuczman, M.; Xerri, L.; Salles, G. A.; Morschhauser, F. |
| Abstract Title: | Validation of the PRIMA-prognostic index for patients treated with rituximab plus chemotherapy and refinement of prognostic parameters for patients on rituximab plus lenalidomide in the phase III relevance trial |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577160402077 |
| DOI: | 10.1182/blood-2019-129024 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1524 -- Source: Wos |
